Polypharma Antidiabetic Drug Dossiers

End-to-end services provided by Polypharma Technologies & Sciences GmbH (Polypharma) include support for development of antidiabetic medicines used to stabilize and control blood glucose levels amongst people with diabetes.

These antidiabetic drug dossiers can be used to empower potential producers seeking fast track ways to develop antidiabetic medicines in oral solid dose form to meet local market needs, particularly across Middle East and North Africa (MENA) markets.

Polypharma drug dossiers are continuously updated to reflect latest research, market trends and regulations.

Antidiabetic agents

There are a number of different types of generic antidiabetic medicines that can be taken in orally combination with insulin to regulate sugar levels in the blood.

Those that Polypharma can already offer as fully developed antidiabetic drug dossiers include

• Acarbose: a generic starch blocker marketed by Bayer in Europe and China as Glucobay and in North America as Precose or Prandase that inhibits alpha glucosidase, an intestinal enzyme that releases glucose from larger carbohydrates.
• Deanol: based on a chemical that is involved in a series of reactions that form acetylcholine, the neurotransmitter chemical that is found in the brain and other areas of the body. Deanol is also used for treating attention deficit-hyperactivity disorder (ADHD), Alzheimer’s disease, autism, and a movement disorder called tardive dyskinesia.
• Empagliflozin: Used to lower blood sugar levels, as well as reduce risk of stroke, heart attack, or death in people who have type 2 diabetes along with heart and blood vessel disease.
• Saxagliptin: From the class of medications called dipeptidyl peptidase-4 (DPP-4) inhibitors, it is prescribed in combination with diet and exercise to lower blood sugar levels in patients with type 2 diabetes.
• Nicotinamide: Also called niacinamide, this is a form of vitamin B3 required for the function of fats and sugars in the body and to maintain healthy cells.

Antidiabetic drug dossiers in development

The continuously evolving Polypharma R&D pipeline also includes dossiers in late stage development covering other antidiabetics that include:

• Ezetimibe: From the class of cholesterol-lowering medications, Ezetimibe is used to reduce the amount of cholesterol and other fatty substances in the blood that works by preventing the absorption of cholesterol in the intestine.
• Gliclazide: A sulfonylurea medicine used to treat type 2 diabetes by increasing insulin generation in the pancreas to lower blood sugar, being developed at both standard and slow-release tablets.
• Glimepiride: Another type of sulfonylurea medication that can be used in tablet form as an antidiabetic medication.
• Metformin: An insulin sensitizer antidiabetic agent that reduces serum glucose level by several different mechanisms as an alternative to increasing insulin secretion in the pancreas. Rather it  increases the effects of natural insulin by suppressing endogenous glucose production by the liver, by reducing the rate of gluconeogenesis and glycogenolysis.

Polypharma  is also developing dossiers for Vitamin D3 and Calcium supplements.

Antiemetic drugs

Polypharma also offers its partners across the MENA region a portfolio of antiemetic medicines in oral dose formulations to reduce nausea and vomiting that can stem from motion sickness, viral or bacterial infections, pregnancy, effects of surgery or in chemotherapy.

These medications work by blocking neurotransmitter chemical messengers and include diphenhydramine or dimenhydrinate, dexamethasone, and prochlorperazine.

Polypharma is also able to develop new antidiabetic dossiers on request and after having carried out a specific feasibility study on the substance.

Resources

Click on Generic human medicine drugs for further information.
Click on Generic drug dossier development  for further information.